Author:
Sandach P.,Fendler W. P.,Herrmann K.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Ahmadzadehfar H, Albers P, Bockisch A et al (2018) Lutetium-177-PSMA radioligand therapy : consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Dusseldorf, Essen, and cologne and the MDK Nordrhein. Urologe A 57:709–713
2. Ahmadzadehfar H, Rahbar K, Kurpig S et al (2015) Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res 5:114
3. Claringbold PG, Turner JH (2016) Pancreatic neuroendocrine tumor control: durable objective response to combination 177Lu-Octreotate-capecitabine-temozolomide radiopeptide chemotherapy. Neuroendocrinology 103:432–439
4. Culp MB, Soerjomataram I, Efstathiou JA et al (2019) Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. https://doi.org/10.1016/j.eururo.2019.08.005
5. Demirci E, Sahin OE, Ocak M et al (2016) Normal distribution pattern and physiological variants of 68 Ga-PSMA-11 PET/CT imaging. Nucl Med Commun 37:1169–1179
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献